Skip to main content

CCTG Connection



Published:
Category: Group updates
CCTG Recognition Awards - Call for Nominations
The Canadian Cancer Trials Group is seeking nominations for the 2025 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group. We are seeking nominations for the following Recognition Awards: Read More

Published:
Category: News
CIHR funding announced to investigate preventative treatments for infections in patients with hematologic cancer patients

The CCTG SC30 (RATIONAL) trial has been successfully funded through the CIHR fall competition for nearly $1.2 million over four years. The study will investigate treatment options for patients with blood cancers and low antibody levels to determine the best supportive care interventions to prevent serious infections. 

Read More

Published:
Category: News
Dr. Philippe Bedard

The European Society for Medical Oncology (ESMO) has announced that the recipient of the 2025 TAT Honorary Award is Philippe Bedard, Professor of Medicine at the University of Toronto, Staff Medical Oncologist in the Division of Medical Oncology, Director of the Cancer Genomics Program, and a Principal Investigator in the Bras Drug Development Program at the Princess

Read More

Published:
Category: News
CIHR funding announced for CCTG PAC5 investigating a treatment for complications after pancreatic surgery

The Canadian Cancer Trials Group (CCTG) has been awarded $742,052 for the PAC5 clinical trial in the CIHR Fall 2024 Project Grant competition. This phase III trial will test lanreotide for the prevention of one of the most severe complications of pancreatic surgery, postoperative pancreatic fistula (POPF).

“The PAC5 clinical trial has the potential to change the standard of care for postoperative pancreatic fistula prophylaxis, significantly benefiting patients and reducing healthcare system costs,” says CCTG Senior Investigator, Chris O’Callaghan.

Read More

Published:
Category: Publications
Publication: CE9

Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre,open-label,multiarm, biomarker-directed,signal-seeking,umbrella,clinical trial for recurrent IDH mutant,grade 2/3 glioma

Read More



Published:
Category: Group updates
2025-2026 New Investigator Cancer Trials Practicum group

The 2024 - 2025 CCTG New Investigator Clinical Trial Practicum is now accepting applications!

Read More

Published:
Category: Group updates
 2025 Annual Spring Meeting of Participants
An update on the CCTG Annual Spring Meeting of Participants, which will be held from Friday, April 25 to Sunday, April 27 at the Chelsea Hotel in Toronto. Read More

Published:
Category: Publications
Tumor-Free ctDNA testing supports organ preservation for rectal cancer patients

The CCTG CO28 correlative study: Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation, was presented by Dr Jonathan Loree at GI ASCO 2025. This oral abstract assessed circulating tumor DNA (ctDNA) in patients with T1-T3, N0 rectal cancer and found that ctDNA effectively identifies cancers with inadequate response to chemotherapy for which a more radical surgery is recommended.

Read More